Objective: We sought to determine whether the Val 158 Met polymorphism in the catechol-Omethyltransferase (COMT) gene influences neurodegeneration within dopamine-innervated brain regions.
Each neurodegenerative disease is characterized by a prototypical regional distribution 1 but also by significant anatomical heterogeneity. Autosomal dominant genes cause dementia in a minority of patients, while in sporadic disease genetic background may confer increased risk or earlier age at onset. 2 Little attention has been paid, however, to genes that produce clinical heterogeneity by modifying the injury pattern or severity.
COMT Val 158 Met, a common functional single nucleotide polymorphism (exon 4 G/A; rs4680), influences synaptic dopamine (DA) concentration. The Val allele confers increased enzymatic activity compared to the Met allele at body temperature, resulting in a dosedependent decrease in synaptic DA availability. 3 Studies of healthy volunteers suggest that COMT genotype influences cognitive, reward-related, and emotion processing. 4 -7 Here, we questioned whether the COMT Val 158 Met polymorphism might influence neurodegeneration within brain structures reliant upon dopaminergic neurotransmission. We considered 2 competing hypotheses. Increased DA catabolism might prove deleterious to DA-reliant regions; conversely, reduced synaptic DA availability might protect vulnerable tissues by reducing metabolic demand or by inducing long-term compensatory enhancement of DAinnervated regions. We conducted a wholebrain voxel-wise structural MRI analysis on a large subject pool (n ϭ 252, table 1, tables e-1 and e-2 on the Neurology ® Web site at www.neurology.org) composed of healthy controls and 3 clinical dementia syndromes: Alzheimer disease (AD), behavioral variant frontotemporal dementia (bvFTD), and semantic dementia (SemD). Our findings link COMT genotype to the integrity of DAinnervated regions in patients with neurodegenerative disease.
METHODS Subjects. We searched the University of California, San Francisco (UCSF) Memory and Aging Center (MAC) database for subjects who had undergone COMT genotyping and had a usable 1.5-T MRI scan. Of those, subjects with a clinical diagnosis of AD, bvFTD, or SemD as well as recruited normal controls were included. Patients were required to meet consensus research criteria 8, 9 within 180 days of MRI scanning. Medications were not used as exclusion criteria. All controls were free of neuropsychiatric medications, except 1 on escitalopram and trazodone and 1 on paroxetine, and lacked significant structural abnormalities on MRI. Patients were not on DA-modifying drugs except 1 patient with bvFTD, who took pramipexole. Demographic information is provided in table 1 and tables e-1 and e-2.
Standard protocol approvals, registrations, and patient consents. Procedures were approved by the UCSF Committee on Human Research. All subjects provided informed consent prior to study participation.
Cognitive and neuropsychiatric testing. All subjects underwent a comprehensive neurologic assessment, and the majority underwent additional neuropsychological and functional assessment at the UCSF MAC as described 10 (tables e-1 and e-2). Test scores nearest to the MRI date were included in the analyses, provided that they were obtained within 180 days of scanning. Clinical severity was assessed using the Clinical Dementia Rating (CDR) scale. The Neuropsychiatric Inventory 11 was used to assess 12 domains of behavioral impairment, as well as a total score and an index of caregiver distress.
COMT genotyping. The COMT1 rs4680 SNP was assayed by a TaqMan 5Ј nuclease SNP genotyping assay using 0.125 mL premade Drug Metabolism Assay Mix (C-25746809-50, Applied Biosystems Inc.
[ABI], Carlsbad, CA), 2.5 mL TaqMan master mix (ABI), and 10 ng DNA in a 5 mL total reaction volume. Forward primer: tcaccatcgagatcaacccc; reverse primer: acaacgggtcaggcatgca. Reactions were cycled using the ABI recommended protocol (5 minutes 95°C, 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute in an ABI 9700 thermal cycler). The plates were post read on an ABI 7900HT DNA analyzer and analyzed with SDS v2. 1 12 to ensure that all gray matter is included in the analysis, including atrophic areas of atrophy that can be omitted by default masking procedures.
Statistical analyses. Group differences in demographic and
clinical variables were assessed using parametric testing after normality of the relevant distributions was confirmed. For the whole-brain voxel-based morphometry (VBM) analyses described above, regions identified at a statistical threshold of p Ͻ 0.001, uncorrected, extent threshold ϭ 10 voxels, were considered significant if they fell within a priori hypothesized (DAinnervated) regions of interest in the frontal, temporal, insular, striatal, and midbrain gray matter. Following the VBM analysis, we used the Marsbar toolbox for SPM (http://marsbar.source forge.net/) to extract mean gray matter intensities from the original smoothed, segmented T1-weighted images corresponding to each cluster identified in the all-subjects linear Val dose contrast. We then, as a confirmatory analysis, performed stepwise linear regression to assess whether the effect of COMT genotype on the extracted regional gray matter intensities persisted after accounting for additional potential confounders, including those not modeled in the initial VBM analysis due to concerns regarding the statistical power of the whole-brain assessment. Separate models were created for each cluster, with that cluster's mean gray matter intensity as the dependent variable. The first step of each regression included age at scan, sex, years of education, CDR sum of boxes score, and TIV as the predictors. The second step added diagnosis (modeled as 3 dummy variables to represent the 4 groups), and the third step added Val dose. This approach allowed us to assess the significance of the R 2 change associated with each block of predictor variables. p Values Ͻ0.05 were considered significant; correction for the 7 statistical tests was not applied due to the few tests and the confirmatory nature of these analyses.
Multivariate general linear models were used to evaluate relationships between COMT genotype and cognitive and NPI scores. These analyses were performed on patients only because controls were not routinely administered the NPI. Among the 14 NPI scores, we analyzed the 2 overall scores and the 9 subdomains for which at least 30% of the patients across all diagnostic groups had scores greater than zero (table e-2). Cognitive and NPI scores served as dependent variables in 2 separate models (1 for cognitive scores, 1 for NPI; cases with missing data were excluded listwise). In each model, diagnosis and COMT genotype were entered as fixed factors, and age at scan, sex, education, TIV, and CDR sum of boxes score were entered as covariates. p Values Ͻ0.05 were considered significant.
Relationships between the VBM-identified regions' gray matter intensities and cognitive and NPI scores were assessed in patients using stepwise linear regression. The first step included age at scan, sex, years of education, and TIV as predictors, the second step added diagnosis (modeled as 2 dummy variables to represent the 3 diagnoses), and the third step added all cluster mean gray matter intensities. Cognitive and NPI variables served as the dependent measures in separate models, 1 for each measure. Alpha was set to 0.05, adjusted for 9 cognitive and 11 NPI measures using the Bonferroni method to yield significance thresholds of p ϭ 0.006 (cognitive) and p ϭ 0.005 (NPI).
All analyses were performed in SPSS 19 (IBM, Armonk, NY).
RESULTS

COMT Val
158 Met Val allele dosage predicts greater atrophy within dopamine-innervated brain structures. First, we explored whether the COMT Val 158 Met Val allele exerts dose-dependent linear effects on brain structure. In a whole brain analysis across all subjects, increasing Val allele dosage was associated with decreasing gray matter intensity in only 6 regions ( p Ͻ 0.001, uncorrected; extent threshold ϭ 10 voxels; figure, A, table 2), including clusters in midline ventral midbrain in the vicinity of the VTA, ventromedial prefrontal cortex (vmPFC), bilateral dorsal midinsula/frontal operculum (dMI/FO), left dorsolateral prefrontal cortex (dlPFC), and right ventral striatum (VStr). The identified forebrain structures receive robust dopaminergic innervation via the mesostriatal and mesocortical pathways. 13, 14 Mean gray matter intensities extracted from these clusters for each subject were grouped by genotype and disease status (controls vs patients) and graphed (figure, B). Inspection of these data suggested that the detected linear relationships between Val dose and gray matter intensity were driven primarily by the patients, although the linear trend was also observed in bilateral dMI/FO in controls. In the opposite direction, increasing Val dose correlated with increasing gray matter intensity in only the left hippocampus (table 2) . Follow-up stepwise linear regression analyses (table 3) confirmed that COMT genotype exerted an effect on VBM-identified clusters' mean gray matter intensities, even after accounting for additional potential confounders, including age, sex, education, clinical severity, TIV, and diagnosis. Unexpectedly, patients carrying at least 1 Met allele showed higher gray matter intensity in the region of the VTA compared to controls (figure, B), in contrast to all other COMT-related regions, which exhibited Val dose-dependent reductions in the setting of disease. Unplanned comparisons confirmed that patients with at least 1 Met allele had higher VTA volumes compared to controls of the same COMT genotype (␣ ϭ 0.05; Met/Met: 25 controls vs 38 patients: t ϭ 3.19, p ϭ 0.02; Met/Val: 41 controls vs 81 patients: t ϭ 4.1, p ϭ 8.4E-5), whereas this increase was not detected in Val/Val carriers (17 controls vs 50 patients; t ϭ 0.9, p ϭ 0.35).
158 Met genotype exerts no direct effect on cognition or behavior after controlling for diagnosis.
Next, we sought to determine whether COMT genotype exerted a direct effect on patient cognition (table e-1) or behavior (table e-2) irrespective of diagnosis and other potential confounders. Such an effect might indicate a direct neurochemical influence of COMT genotype. Multivariate analyses, however, revealed no effect of COMT genotype on cognition (patients only, n ϭ 111; ␣ ϭ 0.05, p ϭ 0.175 to 0.960 across cognitive measures) or behavior (patients only, n ϭ 103; ␣ ϭ 0.05, p ϭ 0.381 to 0.981 across NPI scores).
Brain regions influenced by COMT Val
158 Met genotype correlate with cognitive and behavioral function.
Having detected no direct effect of COMT Val 158
Met genotype on cognition or behavior, we examined the influence of COMT-related regions' gray matter intensities on these functional domains in patients.
Stepwise linear regression models demonstrated predictable relationships between cognitive ( Met Val allele acts as a neurodegenerative disease-modifying gene by accentuating gray matter loss within cortical and striatal DA projection targets.
Anatomical heterogeneity within clinical dementia syndromes can be substantial and provides a major source of diagnostic uncertainty. 15, 16 Identifying sources of this individual variation may clarify disease mechanisms and suggest potential disease-modifying therapies. Building on previous work, our findings suggest that a patient's genetic background may skew or exacerbate the anatomical injury pattern. Possession of an APOE ⑀4 allele, for example, worsens atrophy in patients with AD or bvFTD but exerts this effect within regions known for their vulnerability to each disorder. 2 Functional polymorphisms in FOXP2, a gene which when mutated causes a developmental language disorder, are associated with language system hypoperfusion in FTLD. 17 Our data Table 4 Relationships between VBM-identified regional volumes and cognitive scores Regions related to the cognitive measure (after Bonferroni correction). First step predictors include age, sex, education, and total intracranial volume. Second step adds diagnosis and third step adds the 7 identified clusters' mean gray matter intensities.
suggest that COMT Val 158 Met Val allele dosage exerts an effect across dementia syndromes by exacerbating neurodegeneration within regions that receive robust dopaminergic input from the VTA. Although we identified significant genotype effects at an uncorrected statistical threshold within a priori hypothesized (DA-innervated) brain regions, significant regional associations with Val allele dosage did not emerge at the whole-brain level after correcting for multiple comparisons. Compared to disease-related gray matter effects, we anticipated relatively small effects of COMT genotype, and our findings fit with this prediction. The circumscribed pattern of COMT Val
158
Met genotypeassociated regions, as well as the paucity of regions detected by the reverse contrast (more atrophy with increasing Met allele dosage), suggest that the findings are unlikely to reflect Type 1 error.
How synaptic DA availability modulates neurodegeneration merits further study. Healthy Val allele carriers show executive function deficits and inefficient frontal activation during working memory tasks. 18 -23 More recent studies have forged links between COMT Val
Met genotype and normative reward and emotion processing. [5] [6] [7] Lifelong possession of a Val allele could therefore predispose individuals to greater damage to the DA system once a neurodegenerative disease takes hold. Alternatively, reduced DA catabolism, as produced by the Met allele, may increase DA availability and confer resistance to the progressive synaptic transmission deficits that arise in AD, bvFTD, and SemD.
We found increased gray matter in the vicinity of the VTA in patients with at least 1 Met allele compared to genotype-and age-matched healthy controls. Although this unexpected finding requires confirmation in a larger dataset, it challenges conventional views of how neural systems respond to degenerative injury. One potential account of these data is that emerging disease within VTA projection targets disrupts cortical and striatal DA signaling and feeds back on VTA neurons to increase VTA output. Increased VTA activity, in turn, could induce proximal neuronal hypertrophy or increased dendritic arborization, resulting in the increased VTA gray matter intensity observed here. This response, however, appears unattainable by Val allele carriers, suggesting that the compensatory response, whatever its mechanism, may require greater synaptic DA availability.
Previous work in healthy elders and patients with Parkinson disease found no interaction between disease status, COMT Val 158 Met genotype, and regional brain volume. 24 Val allele carriers, however, showed greater age-related atrophy in bilateral dorsal insulae, regions which showed age-and diseaseindependent volume reduction in Val carriers in the present study. Another study in AD showed that the Val allele was associated with more severe psychotic symptoms, such as hallucinations and agitation. 25 Hallucinations were too infrequent in our patient sample to analyze COMT genotype effects, and no significant effects of COMT genotype or COMTrelated clusters' gray matter intensities were found with regard to agitation. Nonetheless, our results and these previous findings support the view that COMT Val 158 Met influences clinico-anatomic features in patients with dementia and that, in the future, knowing a patient's genotype might help predict prognosis and choose treatments. In particular, patients with the diagnoses studied here may benefit from pharmacologic strategies, such as COMT inhibition, which increase synaptic DA availability, thereby mimicking the effect of possessing a COMT Val 158 Met Met allele.
Regions showing Val allele dose-dependent atrophy participate in cognitive, emotional, and rewardrelated processing. Not surprisingly, we found that higher functioning in these domains was associated with structural integrity within COMT Val 158 Met genotype-related brain regions. These findings highlight the behavioral relevance of COMT-related brain regions but do not imply a specific relationship between COMT-related regions and behavior. Perhaps the most striking finding from these analyses, however, was that increasing VTA volume predicted more prominent eating disturbance and overall behavioral impairment. With regard to eating, greater VTA volume could predispose patients to heightened limbic striatal DA release in response to rewarding food stimuli; this hypothesis could be addressed in future studies.
Despite the large clinical cohorts available, this study was limited by smaller sample sizes once each clinical syndrome was divided by genotype. This constraint prevented us from exploring potentially relevant interactions, such as sex-specific influences of COMT genotype on brain volume. Future larger studies may help address this issue and add security to our major findings. The present findings suggest that genetic background exerts a predictable influence on patterns of regional neurodegeneration. The results have potential treatment implications, suggesting that patients harboring a Val allele may benefit from COMT inhibition and justifying exploration of COMT inhibitors as neuroprotective agents for patients with the disorders studied here. Despite the increasing feasibility of more exhaustive genotyping and gene-imaging correlations, this work provides a model for exploring how single gene polymorphisms influence system-specific brain structures. Future studies could explore effects of other neuromodulatory gene poly-morphisms, with the goal of clarifying disease mechanisms and identifying potential new symptomatic or neuroprotective therapies.
